$2.38 0.2 8.2%
Last Trade - 03/03/21
| Market Cap | £270.0m |
| Enterprise Value | £269.8m |
| Revenue | £59.5k |
| Position in Universe | 3783rd / 6643 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.11 | 0.21 | 0.13 | +8.6% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioNexus Gene Lab Corporation is a molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. The Company is engaged in developing and marketing non-invasive blood tests for early detection of diseases. The Company’s non-invasive blood tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of over 11 different diseases. Bionexus Gene Lab Sdn. Bdh. is the subsidiary of the Company.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| No. of Shareholders: | n/a |
| No. of Employees: | 5 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 171,218,152 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 905 Broadway St Ste 100, KUALA LUMPUR, 59200, Malaysia |
| Web | https://www.bionexusgenelab.com/ |
| Phone | + |
| Contact | () |
| Auditors | Total Asia Associates |
As of 03/03/21, shares in BioNexus Gene Lab are trading at $2.38, giving the company a market capitalisation of £270.0m. This share price information is delayed by 15 minutes.
Shares in BioNexus Gene Lab are currently trading at $2.38 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioNexus Gene Lab price has moved by % over the past year.
There are no analysts currently covering BioNexus Gene Lab.
BioNexus Gene Lab is scheduled to issue upcoming financial results on the following dates:
BioNexus Gene Lab does not currently pay a dividend.
BioNexus Gene Lab does not currently pay a dividend.
BioNexus Gene Lab does not currently pay a dividend.
To buy shares in BioNexus Gene Lab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in BioNexus Gene Lab are currently trading at $2.38, giving the company a market capitalisation of £270.0m.
Here are the trading details for BioNexus Gene Lab:
Based on an overall assessment of its quality, value and momentum, BioNexus Gene Lab is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for BioNexus Gene Lab.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioNexus Gene Lab. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $2.38, shares in BioNexus Gene Lab are trading at 7.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for BioNexus Gene Lab.
We were unable to find the directors for BioNexus Gene Lab.
Here are the top five shareholders of BioNexus Gene Lab based on the size of their shareholding:
